MDC CONNECTS WEBINARS
TARGET VALIDATION AND EFFICACY

  • Strategies for target and pathway engagement in cellular assays - Matt Burnham, MDC
  • Go native… Characterising therapeutic effect in primary cellular models - Amanda Woodrooffe, Precision for Medicine
  • Use of pre-clinical models to deliver proof of concept efficacy - Lorraine Mooney, Sygnature Discovery

2pm BST, 3rd June 2020

Book your place

© Medicines Discovery Catapult 2020. All rights reserved. Read our Privacy Policy

Is my Compound Safe?
2pm BST, Wednesday 10th June 2020

  • Making safety part of drug design - Richard Knight, Apconix
  • How to get your molecule into humans: A practical guide for the present and a look to the future - Pauline Garner, Sequani
  • Challenges and opportunities of complex cell models in toxicity testing - Malcolm Haddrick, MDC

Register for this webinar >

Developing a Biomarker Strategy
2pm BST, Wednesday 17th June 2020

  • Designing a biomarker strategy - Gayle Marshall, MDC
  • The challenges of accessing clinical samples - Helen Hind, MDC
  • Biomarker identification: Assessing immune function - Russell Garland, Charles River Laboratories

Register for this webinar >

Other webinars in the series

About the presenters

Amanda Woodrooffe, PhD

Amanda has 25 years’ experience in drug discovery and in vitro ADME gained from her roles in the biopharma and CRO industries.  She has been responsible for operations management and scientific leadership of the UK-based discovery research services business for Asterand / BioIVT since 2010, This business has very recently been acquired by Precision for Medicine, becoming their 2nd European laboratory operation.  Prior to this, Amanda held various positions responsible for developing business to business partnerships, pharmaceutical licensing, patent portfolio management and supporting corporate development. Amanda received her PhD from the University of Cambridge.

Dr Matthew Burnham

Matthew is a Lead Scientist at MDC. He has expertise in drug discovery with 9 years previous experience at AstraZeneca in both the Mechanistic Biology and Profiling Department and the Safety Screening Centre, developing and validating cellular assays for drug efficacy studies and building understanding for predictive in vitro toxicology. Previously in academia, he specialised in elucidation of complex molecular pathways and electrophysiology of vascular biology as a BHF investigator.

Lorraine Mooney

An experienced Bioscientist with in vivo pharmacology expertise and 15 years’ experience in Oncology Drug Discovery both at AstraZeneca and in contract research.  Lorraine has delivered pre-clinical in vivo strategies for large and small molecule drug discovery projects from identifying leads through to supporting early clinical development.  Lorraine has expansive knowledge of tumour xenograft models as well as significant experience of utilising syngeneic models to support immune oncology targets.  Lorraine received her PhD in Cancer Biology from the University of Sheffield and completed two Postdoctoral Research Positions, studying Stress Kinase Cell Signalling Pathways at the University of Manchester and then at AstraZeneca exploring in vivo optical imaging techniques.